Purchase Order 75N91019P00092

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $4,662.50 on July 20, 2017, for DNA extraction services. Place of performance is Seattle, Washington. The order carries a firm fixed-price structure with an ultimate completion date of August 18, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for DNA extraction services valued at $12,475.00, with an award date of April 3, 2019 and ultimate completion on May 3, 2019. Work is performed in Seattle, Washington. No set-aside applies. The order is priced on a firm fixed-price basis for commercial laboratory services.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $197,125 on July 22, 2014, covering service delivery of 40,000 input genomes and 200,000 TCR sequences survey work. Place of performance is Bethesda, Maryland. The order carries a firm fixed-price structure with an ultimate completion date of April 23, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $14,274.88 on March 4, 2014, to perform T-cell receptor deep sequencing on 40 samples total. Performance is located in Bethesda, Maryland. The order is firm fixed price with an ultimate completion date of September 11, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $11,930.00 on August 2, 2018, with an ultimate completion date of September 28, 2018. Work is performed in Seattle, Washington. The order procures immunosequencing services and diagnostic testing delivered under firm fixed-price pricing.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $4,587.50 on August 24, 2017, for DNA services. Performance is located in San Diego, California, with an ultimate completion date of September 30, 2017. The order carries firm fixed price terms.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation valued at $19,350 on September 6, 2018, with completion by November 12, 2018. Place of performance is Seattle, Washington. The order is firm fixed price with no set-aside designation. Adaptive Biotechnologies, a Seattle-based biotechnology company, supplies immunosequencing services and minimal residual disease diagnostic testing to federal health research and defense medical agencies.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $19,550.00 on July 24, 2018. Performance is located in Seattle, Washington. The order, with an ultimate completion date of August 19, 2018, procures immunosequencing services delivered under firm fixed-price terms. No set-aside was used.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $6,750.00 on August 29, 2017, with completion scheduled for September 30, 2017. Performance is located in San Diego, California. The order covers DNA services using Adaptive's immunosequencing capabilities. This is a firm fixed-price acquisition with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $9,987.50 on January 4, 2018, with completion scheduled for February 4, 2018. Work is performed in Piscataway, New Jersey. The order covers DNA services and adaptive biotechnology testing. Pricing is firm fixed price.</p>